Literature DB >> 27881650

Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.

Anjuman Ara1, Robin P Love1, Tyson B Follack1, Khawaja A Ahmed1, Madison B Adolph1, Linda Chelico2.   

Abstract

The APOBEC3 (A3) enzymes, A3G and A3F, are coordinately expressed in CD4+ T cells and can become coencapsidated into HIV-1 virions, primarily in the absence of the viral infectivity factor (Vif). A3F and A3G are deoxycytidine deaminases that inhibit HIV-1 replication by inducing guanine-to-adenine hypermutation through deamination of cytosine to form uracil in minus-strand DNA. The effect of the simultaneous presence of both A3G and A3F on HIV-1 restriction ability is not clear. Here, we used a single-cycle infectivity assay and biochemical analyses to determine if coencapsidated A3G and A3F differ in their restriction capacity from A3G or A3F alone. Proviral DNA sequencing demonstrated that compared to each A3 enzyme alone, A3G and A3F, when combined, had a coordinate effect on hypermutation. Using size exclusion chromatography, rotational anisotropy, and in vitro deamination assays, we demonstrate that A3F promotes A3G deamination activity by forming an A3F/G hetero-oligomer in the absence of RNA which is more efficient at deaminating cytosines. Further, A3F caused the accumulation of shorter reverse transcripts due to decreasing reverse transcriptase efficiency, which would leave single-stranded minus-strand DNA exposed for longer periods of time, enabling more deamination events to occur. Although A3G and A3F are known to function alongside each other, these data provide evidence for an A3F/G hetero-oligomeric A3 with unique properties compared to each individual counterpart. IMPORTANCE: The APOBEC3 enzymes APOBEC3F and APOBEC3G act as a barrier to HIV-1 replication in the absence of the HIV-1 Vif protein. After APOBEC3 enzymes are encapsidated into virions, they deaminate cytosines in minus-strand DNA, which forms promutagenic uracils that induce transition mutations or proviral DNA degradation. Even in the presence of Vif, footprints of APOBEC3-catalyzed deaminations are found, demonstrating that APOBEC3s still have discernible activity against HIV-1 in infected individuals. We undertook a study to better understand the activity of coexpressed APOBEC3F and APOBEC3G. The data demonstrate that an APOBEC3F/APOBEC3G hetero-oligomer can form that has unique properties compared to each APOBEC3 alone. This hetero-oligomer has increased efficiency of virus hypermutation, raising the idea that we still may not fully realize the antiviral mechanisms of endogenous APOBEC3 enzymes. Hetero-oligomerization may be a mechanism to increase their antiviral activity in the presence of Vif.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  APOBEC3; DNA-protein interactions; HIV; deaminase; mutagenesis; oligomerization; processivity; protein-protein interactions; reverse transcriptase

Mesh:

Substances:

Year:  2017        PMID: 27881650      PMCID: PMC5244329          DOI: 10.1128/JVI.02230-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Authors:  Linda Chelico; Phuong Pham; Peter Calabrese; Myron F Goodman
Journal:  Nat Struct Mol Biol       Date:  2006-04-23       Impact factor: 15.369

Review 3.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

4.  The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.

Authors:  Chunling Hu; Dyana T Saenz; Hind J Fadel; William Walker; Mary Peretz; Eric M Poeschla
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

5.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

6.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

7.  Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.

Authors:  Markus-Frederik Bohn; Shivender M D Shandilya; John S Albin; Takahide Kouno; Brett D Anderson; Rebecca M McDougle; Michael A Carpenter; Anurag Rathore; Leah Evans; Ahkillah N Davis; Jingying Zhang; Yongjian Lu; Mohan Somasundaran; Hiroshi Matsuo; Reuben S Harris; Celia A Schiffer
Journal:  Structure       Date:  2013-05-16       Impact factor: 5.006

8.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

9.  Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.

Authors:  Anjuman Ara; Robin P Love; Linda Chelico
Journal:  PLoS Pathog       Date:  2014-03-20       Impact factor: 6.823

10.  RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.

Authors:  Hendrik Huthoff; Flavia Autore; Sarah Gallois-Montbrun; Franca Fraternali; Michael H Malim
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

View more
  20 in total

Review 1.  New targets for HIV drug discovery.

Authors:  Ana C Puhl; Alfredo Garzino Demo; Vadim A Makarov; Sean Ekins
Journal:  Drug Discov Today       Date:  2019-03-15       Impact factor: 7.851

2.  An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (Macaca leonina) That May Reduce APOBEC3G-Mediated Hypermutation Pressure on HIV-1.

Authors:  Xiao-Liang Zhang; Meng-Ting Luo; Jia-Hao Song; Wei Pang; Yong-Tang Zheng
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 3.  A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.

Authors:  Ryan P Bennett; Jason D Salter; Harold C Smith
Journal:  Trends Mol Med       Date:  2018-03-30       Impact factor: 11.951

4.  Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA.

Authors:  Yao Fang; Xiao Xiao; Shu-Xing Li; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2017-11-27       Impact factor: 5.469

5.  Divergence in Dimerization and Activity of Primate APOBEC3C.

Authors:  Amit Gaba; Mark A Hix; Sana Suhail; Ben Flath; Brock Boysan; Danielle R Williams; Tomas Pelletier; Michael Emerman; Faruck Morcos; G Andrés Cisneros; Linda Chelico
Journal:  J Mol Biol       Date:  2021-10-16       Impact factor: 6.151

Review 6.  SERINC as a Restriction Factor to Inhibit Viral Infectivity and the Interaction with HIV.

Authors:  Gracia Viviana Gonzalez-Enriquez; Martha Escoto-Delgadillo; Eduardo Vazquez-Valls; Blanca Miriam Torres-Mendoza
Journal:  J Immunol Res       Date:  2017-11-22       Impact factor: 4.818

7.  Cytidine deaminase efficiency of the lentiviral viral restriction factor APOBEC3C correlates with dimerization.

Authors:  Madison B Adolph; Anjuman Ara; Yuqing Feng; Cristina J Wittkopp; Michael Emerman; James S Fraser; Linda Chelico
Journal:  Nucleic Acids Res       Date:  2017-04-07       Impact factor: 16.971

8.  Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.

Authors:  Michael Morse; Ran Huo; Yuqing Feng; Ioulia Rouzina; Linda Chelico; Mark C Williams
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

9.  APOBEC3F Constitutes a Barrier to Successful Cross-Species Transmission of Simian Immunodeficiency Virus SIVsmm to Humans.

Authors:  Rayhane Nchioua; Dorota Kmiec; Amit Gaba; Christina M Stürzel; Tyson Follack; Stephen Patrick; Andrea Kirmaier; Welkin E Johnson; Beatrice H Hahn; Linda Chelico; Frank Kirchhoff
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

Review 10.  Examination of the APOBEC3 Barrier to Cross Species Transmission of Primate Lentiviruses.

Authors:  Amit Gaba; Ben Flath; Linda Chelico
Journal:  Viruses       Date:  2021-06-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.